Cargando…

Effects of Liraglutide on Cardiovascular Outcomes in Type 2 Diabetes Patients With and Without Baseline Metformin Use: Post Hoc Analyses of the LEADER Trial

Detalles Bibliográficos
Autores principales:	Crowley, Matthew J., McGuire, Darren K., Alexopoulos, Anastasia-Stefania, Jensen, Thomas Jon, Rasmussen, Søren, Saevereid, Hans A., Verma, Subodh, Buse, John B.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Diabetes Association 2020
Materias:	e-Letters: Observations
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7440910/ https://www.ncbi.nlm.nih.gov/pubmed/32647053 http://dx.doi.org/10.2337/dc20-0437

Ejemplares similares

Duration of diabetes and cardiorenal efficacy of liraglutide and semaglutide: A post hoc analysis of the LEADER and SUSTAIN 6 clinical trials
por: Verma, Subodh, et al.
Publicado: (2019)

Response to Comment on Nauck et al. Effects of Liraglutide Compared With Placebo on Events of Acute Gallbladder or Biliary Disease in Patients With Type 2 Diabetes at High Risk for Cardiovascular Events in the LEADER Randomized Trial. Diabetes Care 2019;42:1912–1920
por: Nauck, Michael A., et al.
Publicado: (2020)

The effect of glucagon‐like peptide‐1 receptor agonists liraglutide and semaglutide on cardiovascular and renal outcomes across baseline blood pressure categories: Analysis of the LEADER and SUSTAIN 6 trials
por: Leiter, Lawrence A., et al.
Publicado: (2020)

Effects of glucagon‐like peptide‐1 receptor agonists liraglutide and semaglutide on cardiovascular and renal outcomes across body mass index categories in type 2 diabetes: Results of the LEADER and SUSTAIN 6 trials
por: Verma, Subodh, et al.
Publicado: (2020)

Cardiovascular efficacy of liraglutide and semaglutide in individuals with diabetes and peripheral artery disease
por: Verma, Subodh, et al.
Publicado: (2022)

Renoprotective Effects of the Combination of Empagliflozin and Liraglutide Compared With Roux-en-Y Gastric Bypass in Early-Stage Diabetic Kidney Disease: A Post Hoc Analysis of the Microvascular Outcomes after Metabolic Surgery (MOMS) Randomized Controlled Clinical Trial
por: Cohen, Ricardo V., et al.
Publicado: (2021)

Cardiorenal Outcomes With Ertugliflozin by Baseline Metformin Use: Post Hoc Analyses of the VERTIS CV Trial
por: Cosentino, Francesco, et al.
Publicado: (2022)

Liraglutide and Glycaemic Outcomes in the LEADER Trial
por: Zinman, Bernard, et al.
Publicado: (2018)

Use of Metformin and Cardiovascular Effects of New Classes of Glucose-Lowering Agents: A Meta-analysis of Cardiovascular Outcome Trials in Type 2 Diabetes
por: Zaccardi, Francesco, et al.
Publicado: (2021)

Effect of Cost and Formulation on Persistence and Adherence to Initial Metformin Therapy for Type 2 Diabetes
por: Flory, James H., et al.
Publicado: (2020)

LEADER 2: baseline calcitonin in 9340 people with type 2 diabetes enrolled in the Liraglutide Effect and Action in Diabetes: Evaluation of cardiovascular outcome Results (LEADER) trial: preliminary observations
por: Daniels, G H, et al.
Publicado: (2015)

Cardiovascular Risk Reduction With Liraglutide: An Exploratory Mediation Analysis of the LEADER Trial
por: Buse, John B., et al.
Publicado: (2020)

Assessing the Association Between GLP-1 Receptor Agonist Use and Diabetic Retinopathy Through the FDA Adverse Event Reporting System
por: Wang, Tiansheng, et al.
Publicado: (2019)

Assessing the Association Between Dipeptidyl Peptidase 4 Inhibitor Use and Inflammatory Bowel Disease Through Drug Adverse Event Reporting
por: Wang, Tiansheng, et al.
Publicado: (2019)

Cardiovascular outcomes in patients who experienced a myocardial infarction while treated with liraglutide versus placebo in the LEADER trial
por: Nauck, Michael A, et al.
Publicado: (2018)

Sodium–Glucose Cotransporter 2 Inhibitors and Diabetic Ketoacidosis: A Case Series From Three Academic Institutions
por: Misaghian-Xanthos, Negin, et al.
Publicado: (2017)

Dipeptidyl Peptidase 4 Inhibitors and Risk of Inflammatory Bowel Disease Among Patients With Type 2 Diabetes: A Meta-analysis of Randomized Controlled Trials
por: Li, Guangyao, et al.
Publicado: (2019)

Effect of the Glucagon-Like Peptide-1 Receptor Agonists Semaglutide and Liraglutide on Kidney Outcomes in Patients With Type 2 Diabetes: Pooled Analysis of SUSTAIN 6 and LEADER
por: Shaman, Ahmed M., et al.
Publicado: (2021)

Potential kidney protection with liraglutide and semaglutide: Exploratory mediation analysis
por: Mann, Johannes F. E., et al.
Publicado: (2021)

Impact of microvascular disease on cardiovascular outcomes in type 2 diabetes: Results from the LEADER and SUSTAIN 6 clinical trials
por: Verma, Subodh, et al.
Publicado: (2020)

Coadministration of Liraglutide With Tacrolimus in Kidney Transplant Recipients: A Case Series
por: Pinelli, Nicole R., et al.
Publicado: (2013)

Benefits of combination of insulin degludec and liraglutide are independent of baseline glycated haemoglobin level and duration of type 2 diabetes
por: Rodbard, H. W., et al.
Publicado: (2016)

Liraglutide suppresses the proliferation of endometrial cancer cells through the adenosine 5′-monophosphate (AMP)-activated protein kinase signaling pathway
por: Zhu, Xin-Xin, et al.
Publicado: (2021)

Temporal Trends in Lower-Limb Major and Minor Amputation and Revascularization Procedures in People With Diabetes in England During the COVID-19 Pandemic
por: Valabhji, Jonathan, et al.
Publicado: (2021)

Lower rates of cardiovascular events and mortality associated with liraglutide use in patients treated with basal insulin: A DEVOTE subanalysis (DEVOTE 10)
por: Brown‐Frandsen, Kirstine, et al.
Publicado: (2019)

Semaglutide reduces cardiovascular events regardless of metformin use: a post hoc subgroup analysis of SUSTAIN 6 and PIONEER 6
por: Husain, Mansoor, et al.
Publicado: (2022)

Changes in Albuminuria Predict Cardiovascular and Renal Outcomes in Type 2 Diabetes: A Post Hoc Analysis of the LEADER Trial
por: Persson, Frederik, et al.
Publicado: (2021)

Synergistic anti-tumor effects of liraglutide with metformin on pancreatic cancer cells
por: Lu, Ran, et al.
Publicado: (2018)

Baseline Anxiety and Depression and Risk for ICU Delirium: A Prospective Cohort Study
por: Wu, Ting Ting, et al.
Publicado: (2022)

LEADER 3—Lipase and Amylase Activity in Subjects With Type 2 Diabetes: Baseline Data From Over 9000 Subjects in the LEADER Trial
por: Steinberg, William M., et al.
Publicado: (2014)

Follow the LEADER—Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results Trial
por: Kalra, Sanjay
Publicado: (2016)

Baseline moderate-range albuminuria is associated with protection against severe COVID-19 pneumonia
por: Bashkin, Amir, et al.
Publicado: (2022)

Effects of liraglutide on extraglycemic inflammatory markers and renal hemodynamic parameters in diabetic kidney disease (DKD)
por: Song, Wenjuan, et al.
Publicado: (2023)

Glycated Hemoglobin in 14,850 Adolescent Blood Donors: A Pilot Screening Program
por: Gore, M. Odette, et al.
Publicado: (2014)

Practical Primer Addressing Real-World Use Scenarios of Subcutaneous Vedolizumab in Ulcerative Colitis and Crohn’s Disease: Post Hoc Analyses of VISIBLE Studies
por: Sandborn, William J, et al.
Publicado: (2023)

Effect of metformin versus metformin plus liraglutide on gonadal and metabolic profiles in overweight patients with polycystic ovary syndrome
por: Xing, Chuan, et al.
Publicado: (2022)

Effects of insulin and the glucagon‐like peptide 1 receptor agonist liraglutide on the kidney proteome in db/db mice
por: Liljedahl, Leena, et al.
Publicado: (2017)

Cardiovascular and renal outcomes by baseline albuminuria status and renal function: Results from the LEADER randomized trial
por: Mosenzon, Ofri, et al.
Publicado: (2020)

Applying REWIND cardiovascular disease criteria to SUSTAIN 6 and PIONEER 6: An exploratory analysis of cardiovascular outcomes with semaglutide
por: Verma, Subodh, et al.
Publicado: (2021)

Gut microbiome differences between metformin‐ and liraglutide‐treated T2DM subjects
por: Wang, Zhang, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_5ug5g5upkfama6savd4lpbih25